{"id":1798,"date":"2017-01-19T12:23:26","date_gmt":"2017-01-19T12:23:26","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=1798"},"modified":"2021-07-24T12:56:38","modified_gmt":"2021-07-24T07:26:38","slug":"the-business-cocktail-7","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-7","title":{"rendered":"Astellas ditches UMN Pharma; J&#038;J, Actelion land on a price; Bayer\u2019s pledge; Biogen to fork over $1.25B-plus"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a08710c705ea\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a08710c705ea\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-7\/#With_Flublok_at_a_standstill_in_Japan_Astellas_ditches_collaborator_UMN_Pharma\" >With Flublok at a standstill in Japan, Astellas ditches collaborator UMN Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-7\/#Deal-talkers_J_J_Actelion_reportedly_land_on_a_price_but_spinoff_details_still_pending\" >Deal-talkers J&amp;J, Actelion reportedly land on a price, but spinoff details still pending<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-7\/#To_win_Trumps_deal_backing_Bayer_made_a_new_8B-plus_pledge\" >To win Trump&#8217;s deal backing, Bayer made a new $8B-plus pledge.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-7\/#Biogen_to_fork_over_125B-plus_to_settle_blockbuster_Tecfidera_patent_fight_with_Forward\" >Biogen to fork over $1.25B-plus to settle blockbuster Tecfidera patent fight with Forward<\/a><\/li><\/ul><\/nav><\/div>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"With_Flublok_at_a_standstill_in_Japan_Astellas_ditches_collaborator_UMN_Pharma\"><\/span>With Flublok at a standstill in Japan, Astellas ditches collaborator UMN Pharma<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">After Japanese regulators turned away the partners\u2019 submission for a new cell-culture flu vaccine, Astellas has pulled the plug on a collaboration with UMN Pharma. UMN said it\u2019s \u201cregrettable\u201d the companies can no longer work together to push the vaccine, Protein Sciences\u2019 Flublok, to the market in Japan. The pharmas first linked up back in 2010. The shot had previously met its endpoints in a phase 3 trial, according to a release from UMN, and development partner Astellas submitted a marketing application to Japanese health authorities in May 2014. The Pharmaceuticals and Medical Devices Agency considered the risks and benefits, and notified Astellas that it would not further conduct its review; Astellas moved to withdraw the app.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Deal-talkers_J_J_Actelion_reportedly_land_on_a_price_but_spinoff_details_still_pending\"><\/span>Deal-talkers J&amp;J, Actelion reportedly land on a price, but spinoff details still pending<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Johnson &amp; Johnson and Actelion may have finally settled a key condition of their long-discussed transaction. The pair has landed on a price for the deal, although sources didn\u2019t tell what that price was. J&amp;J was considering a price in the $260-per-share range for Actelion\u2019s marketed meds, a figure that would bring the buy to more than $28 billion. J&amp;J\u2019s courtship of the Swiss biotech has been a long one, in part thanks to Actelion founder and CEO Jean-Paul Clozel\u2019s desire to keep a piece of his company flying solo.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"To_win_Trumps_deal_backing_Bayer_made_a_new_8B-plus_pledge\"><\/span>To win Trump&#8217;s deal backing, Bayer made a new $8B-plus pledge.<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Bayer\u2019s $66 billion Monsanto takeover has plenty of critics. But thanks to an $8 billion R&amp;D pledge, it has one key backer: U.S. President-elect Donald Trump. Bayer and Monsanto said that their respective CEOs\u2014Werner Baumann and Hugh Grant\u2014had a \u201cvery productive\u201d meeting with Trump and his team, resulting in a pledge to promise $16 billion or more in agriculture R&amp;D over the next six years, with at least half of that coming in the U.S.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Biogen_to_fork_over_125B-plus_to_settle_blockbuster_Tecfidera_patent_fight_with_Forward\"><\/span>Biogen to fork over $1.25B-plus to settle blockbuster Tecfidera patent fight with Forward<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Biogen has settled its Tecfidera patent fight with Forward Pharma for a whopping $1.25 billion in upfront cash. And if Forward wins particular patent rights on its rival drug, Biogen will be on the hook for Tecfidera royalties of at least 10%. Forward shares skyrocketed 83% to a $33.28 high in premarket trading on Tuesday after Biogen announced the deal. Although the companies still have issues to resolve, the agreement gives Biogen a license to all of Forward\u2019s related intellectual property, and it grants the Danish company potential royalties on Tecfidera, a product that brought in nearly $2.4 billion in sales in the first nine months of 2016 alone. Forward is developing a potential Tecfidera competitor now dubbed FP187.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>With Flublok at a standstill in Japan, Astellas ditches collaborator UMN Pharma After Japanese regulators turned away the partners\u2019 submission for a new cell-culture flu vaccine, Astellas has pulled the plug on a collaboration with UMN Pharma. UMN said it\u2019s \u201cregrettable\u201d the companies can no longer work together to push the vaccine, Protein Sciences\u2019 Flublok, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1326,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[117,134,204,749],"industry":[17225],"therapeutic_areas":[17227],"class_list":["post-1798","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-biopharmaceutical","tag-business-consultant","tag-delveinsight","tag-pharmaceutical-market","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Astellas ditches UMN Pharma; J&amp;J, Actelion land on a price<\/title>\n<meta name=\"description\" content=\"After Japanese regulators turned away the partners\u2019 submission for a new cell-culture flu vaccine, Astellas has pulled the plug on a collaboration...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-7\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Astellas ditches UMN Pharma; J&amp;J, Actelion land on a price\" \/>\n<meta property=\"og:description\" content=\"After Japanese regulators turned away the partners\u2019 submission for a new cell-culture flu vaccine, Astellas has pulled the plug on a collaboration...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-7\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-01-19T12:23:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/10\/09021339\/images.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"288\" \/>\n\t<meta property=\"og:image:height\" content=\"175\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Astellas ditches UMN Pharma; J&J, Actelion land on a price","description":"After Japanese regulators turned away the partners\u2019 submission for a new cell-culture flu vaccine, Astellas has pulled the plug on a collaboration...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-7","og_locale":"en_US","og_type":"article","og_title":"Astellas ditches UMN Pharma; J&J, Actelion land on a price","og_description":"After Japanese regulators turned away the partners\u2019 submission for a new cell-culture flu vaccine, Astellas has pulled the plug on a collaboration...","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-7","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-01-19T12:23:26+00:00","article_modified_time":"2021-07-24T07:26:38+00:00","og_image":[{"width":288,"height":175,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/10\/09021339\/images.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-7","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-7","name":"Astellas ditches UMN Pharma; J&J, Actelion land on a price","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-7#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-7#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/10\/09021339\/images.jpg","datePublished":"2017-01-19T12:23:26+00:00","dateModified":"2021-07-24T07:26:38+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"After Japanese regulators turned away the partners\u2019 submission for a new cell-culture flu vaccine, Astellas has pulled the plug on a collaboration...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-7"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-7#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/10\/09021339\/images.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/10\/09021339\/images.jpg","width":288,"height":175},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/10\/09021339\/images.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">biopharmaceutical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Business Consultant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharmaceutical Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">biopharmaceutical<\/span>","<span class=\"advgb-post-tax-term\">Business Consultant<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jan 19, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jan 19, 2017 12:23 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1798"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1798\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1326"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1798"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1798"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1798"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1798"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}